TearSolutions

Executive Summary

TearSolutions is a privately held ophthalmology company developing Lacripep, a first-in-class peptide therapy designed to restore the natural tear film and treat ocular surface diseases such as dry eye disease. The therapy mimics the activity of lacritin, a naturally occurring tear protein that promotes corneal epithelial health and neuronal integrity. TearSolutions recently completed a first-in-human study, with results published in Cornea, demonstrating safety and preliminary efficacy. The company is now advancing into Phase 1/2 clinical trials to further evaluate Lacripep's potential as a disruptive therapy for millions of patients suffering from chronic dry eye and related conditions. With a novel mechanism of action and a strong scientific foundation, TearSolutions aims to address a significant unmet need in the ocular surface disease market, which currently lacks effective long-term treatments. The company is based in Charlottesville, VA, and was founded in 2021.

Upcoming Catalysts (preview)

• Q2 2026Initiation of Phase 2 trial for Lacripep in dry eye disease70% success
• H2 2026Strategic partnership or licensing deal for commercialization50% success
• Q3 2026FDA Orphan Drug Designation or Fast Track status80% success